Robinson, H. R. (2018). A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. American Society of Hematology (ASH).
Chicago Style (17th ed.) CitationRobinson, H. R. A CD19/CD3 Bispecific Antibody for Effective Immunotherapy of Chronic Lymphocytic Leukemia in the Ibrutinib Era. American Society of Hematology (ASH), 2018.
MLA (9th ed.) CitationRobinson, H. R. A CD19/CD3 Bispecific Antibody for Effective Immunotherapy of Chronic Lymphocytic Leukemia in the Ibrutinib Era. American Society of Hematology (ASH), 2018.
Warning: These citations may not always be 100% accurate.